[1] Szczuko M, Zapa?owska-Chwy? M, Drozd A, et al. Effect of IGF-I and TNF-α on intensification of steroid pathways in women with PCOS phenotypes are not identical. Enhancement of progesterone pathway in women with PCOS increases the concentration of TNF-α. Gynecol Endocrinol. 2016;16:1-4.[2] Henning PC, Scofield DE, Rarick KR, et al., “Effects of acute caloric restriction compared to caloric balance on the temporal response of the IGF-I system.” Metabolism. 2013;62(2): 179-187. [3] Gregory SM, Spiering BA, Alemany JA, et al. “Exercise-induced insulin-like growth factor I system concentrations after training in women”. Med Sci Sports Exerc. 2013;4(3): 420-428. [4] Nindl BC, Santtila M, Vaara J, et al. “Circulating IGF-I is associated with fittness and health outcomes in a population of 846 young healthy men.” Growth Horm IGF Res. 2011;21(3):124-128. [5] Khosla S, Melton LJ 3rd, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed?. J Bone Miner Res. 2011;26(3): 441-451. [6] 燕小莉,尹曲华,康冬梅. 骨代谢指标与胰岛素样生长因子1的相关性[J]. 医学综述,2015,21(17):3097-3099.[7] 张金山,罗良平.绝经早期妇女骨密度变化及其与白细胞介素-6、胰岛素样生长因子-1和骨钙素关系的探讨[J]. 实用医学杂志,2011,27(1):54-55.[8] 易伟莲,廖德权,林柏云,等. 绝经后骨质疏松症患者性激素、细胞因子及骨代谢指标的变化及关系[J].检验医学,2012,27(4):296-298.[9] Burch J, Rice S, Yang H, et al. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technol Assess. 2014;18(11): 180.[10] 刘爽,杨梅. 糖尿病骨质疏松症发病机制探讨[J]. 实用糖尿病杂志. 2014, 10(6):59-60.[11] 郭玲,王敏,郝亮.胰岛素样生长因子1对小鼠成骨细胞增殖和碱性磷酸酶活性的影响[J].中国组织工程研究与临床康复, 2010,14(33):6095-6098.[12] Shearer MJ, Newman P. Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis. J Lipid Res. 2014;55(3):345-362.[13] Zoch ML, Clemens TL, Riddle RC. New insights into the biology of osteocalcin. Bone. 2015. pii: S8756-3282.[14] Zhang W,Shen X,Wan C,et al. Effects of insulin and insulin-like growth factor 1 on osteoblast proliferation and differentiation: differential signalling via Akt and ERK. Cell Biochem Funct. 2012;30(4):297-302. [15] Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover,endogenous hormones and risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000;15: 1526-1536.[16] 娄奕萌,丁晓凯,孙文学,等. 胰岛素样生长因子1在慢性肾脏病糖皮质激素性骨质疏松患者诊断中的意义[J]. 浙江医学, 2011,33(12):1763-1765. [17] Niemann I,Hannemann A,Nauck M, et al. The association between insulin-like growth factor I and bone turnover markers in the general adult population. Bone. 2013; 56(1):184-190.[18] 刘亚平,季虹,荣海钦,等. 2 型糖尿病雌性大鼠骨代谢的特点[J]. 中国骨质疏松杂志, 2008,14(1):35-38. [19] 李蔚,孙宜萍,杨建芬.脱氢表雄酮硫酸酯治疗老年男性骨质疏松症120例[J]. 中国组织工程研究与临床康复,2008,12(7):1360-1362. [20] Babatunde OO, Forsyth JJ, Gidlow CJ, et al. A meta-analysis of brief high-impact exercises for enhancing bone health in premenopausal women. Osteoporosis Int. 2012;23(1):109-119.[21] Elbornsson M, Götherström G, Bosæus I, et al. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol. 2012;166(5):787-795. [22] Wu Y, Sun H, Basta-Pljakic J, et al. Serum insulin-like growth factor 1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor. J Bone Miner Res. 2013;28(7): 1575-1586. [23] Elis S,Courtland HW,Wu Y, et al. Elevated serum insulin-like growth factor 1 levels synergize PTH action on the skeleton only when the tissue insulin-like growth factor 1 axis is intact. J Bone Miner Res. 2010; 25(9):2051-2058 [24] Philippou A,Armakolas A,Koutsilieris M. Evidence for the Possible Biological Significance of the insulin-like growth factor 1 Gene Alternative Splicing in Prostate. Cancer.Front Endocrinol. 2013;4:31. [25] Kesavan C,Wergedal JE, Lau KH, et al. Conditional disruption of IGF-I gene in type1α collagen-expressing cells shows an essential role of IGF-I in skeletal anabolic response to loading. Am J Physiol Endocrinol Metab. 2011;301(6):E1191-1197.[26] Mormando M, Nasto LA,Bianchi A,et al. GH receptor is isoforms and skeletal fragility in acromegaly. EurJ Endocrinol. 2014;171(2):237-245.[27] Kamenicky P, Mazziotti G, Lombes M, et al. Growth hormone, insulin-like growth factor-1, and the kidney: path physiological and clinical implications. Endocr Rev. 2014;35(2):234-281. [28] Tritos NA, Klibanski A. Effects of Growth Hormone on Bone. Prog Mol Biol Transl Sci. 2016;138:193-211.[29] Appelman-Dijkstra NM, Claessen KM, Hamdy NA, et al. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. Clin Endocrinol (Oxford). 2014;81(5):727-735.[30] Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta- analysis. J Clin Endocrinal Metab. 2014;99(3):852-860.[31] Crane JL, Cao X. Function of matrix insulin-like growth factor 1 in coupling bone resorption and formation. J Mol Med(Berlin). 2014;92(2):107-115.[32] Wei M, Zheng SZ, Lu Y, et al. Herbal formula menoprogen alters insulin-like growth factor-1 and insulin-like growth factor binding protein-1 levels in the serum and ovaries of an aged female rat model of menopause. Menopause. 2015;22(10):1125-1133. [33] Cavalier E, Souberbielle JC, Gadisseur R, et al. Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients. Clin Biochem. 2014;47(13-14): 1227-1230.[34] Molinelli A, Bonsignore A, Cicconi M, et al. insulin-like growth factor 1 abuse in sport: clinical and medico-legal aspects. J Sports Med Phys Fitness. 2010;50(4):530-535.[35] Sun HB, Chen JC. Prevention of bone loss by injection of insulin-like growth factor-1 after sciatic neurectomy in rats. Chin J Traumatol. 2013;16(3):158-162.[36] Tritos NA, Biller BM. Growth hormone and bone. Curr op in Endocrinol Diab Obes. 2009;16(6):415-422. |